Shots:The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024
Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion
Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report…
Shots: The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024 Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report on the Dealmaker…
Shots: Sticking to M&A and licensing agreements can be really challenging, especially when dealing with stringent antitrust laws and evolving regulatory challenges. In such adverse scenarios, the rational and right step seems to be nullifying the existing deals.In 2023, the termination of the deal between Janssen and Arrowhead remained the talk of the town…
Shots:In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and HealthcareIn 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…
Shots:The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industryIn February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative ColitisPharmaShots has compiled a list of a total…
PharmaShots February Edition magazine explores the elements of dealmaking in the life sciences and healthcare sector. The magazine unfolds an engaging article followed by illustrative infographics and illuminating BioTrends. The magazine sheds light on key regulatory updates and also includes a few amazing facts on collaboration deals, and mergers & acquisitions. PharmaShots welcomed the year…
Shots: In the next installment of Dealmaker 2023, we bring an informative report on the Top M&A based on the Deal Value The report revolves around Pfizer, which signed 16 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases that have summed to a total of $63.23B Propelled by the invaluable…
Shots:As the year began, PharmaShots was busy analyzing the deals throughout 2023 to prepare a special report, viz. JP Morgan 2024 Special: Deal Maker of the Year 2023 (Part 01)The report features Roche, that signed 26 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchasesPropelled by the invaluable…
The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies- as well as government agencies- to partner at unprecedented speed to develop vaccines- treatments- and testsThis article covers the last four months of deal data provided by Chris Dokomajilar of DealFormaOur team at PharmaShots…
The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies- as well as government agencies- to partner at an unprecedented speed to develop vaccines- treatments- and testsThis article covers last four months of deal data provided by Chris Dokomajilar of DealForma.This first part is…
